Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE
12 January 2026
1 min read

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

New York, Jan 12, 2026, 15:40 ET — Regular session

Shares of Dave Inc (DAVE.O) dropped 8.8% to $218.29 in late-afternoon trading Monday, after earlier fluctuating between $212.10 and $247.74. The fintech’s stock had closed Friday at $239.35, with roughly 1.1 million shares changing hands by mid-afternoon, according to market data.

The drop came as investors backed away from credit-sensitive stocks following U.S. President Donald Trump’s call for a one-year cap on credit card interest rates at 10%, starting Jan. 20. On the docket for Tuesday is the U.S. consumer price index (CPI), a crucial inflation measure that could shift expectations around Federal Reserve rate cuts. “We need to see some type of action before the market will actually react to it in a meaningful way,” said Jordan Rizzuto, chief investment officer at GammaRoad Capital Partners.

U.S. stocks were creeping up, the Nasdaq gaining roughly 0.5% and the S&P 500 reaching an intraday record, despite weakness in the financial sector. Peter Cardillo, chief market economist at Spartan Capital Securities in New York, noted the investigation headline involving Fed Chair Jerome Powell had been “telegraphed,” so the market shrugged it off.

Dave’s slump mirrored a wider slide in consumer-finance and fintech stocks. Upstart fell roughly 7.0%, Affirm dropped 6.7%, and SoFi declined 2.8%. LendingClub, however, saw minimal movement.

Dave positions itself as a neobank and fintech platform, offering products like ExtraCash — a 0% interest overdraft through a banking partner — and Dave Checking, a digital deposit account. In 2024, it reported roughly $347 million in revenue and net income near $58 million, according to LSEG data on the Reuters company page.

Monday’s moves can hit smaller consumer fintechs hard, as changes in rate expectations swiftly affect perceptions of funding costs and borrower strain. When sentiment turns sour on lenders, selling often goes too far.

Legal and regulatory clouds loom as well. In late 2024, the U.S. Justice Department lodged a complaint and launched a civil enforcement action against Dave and its CEO, Jason Wilk. They allege the company deceived users over cash advances and imposed hidden fees. Dave pushed back, calling many of the claims inaccurate and pledging a defense. 1

Another risk is that policy chatter hardens into actual rules. A rate cap designed for credit cards won’t necessarily apply to every consumer-finance product. Yet investors often sell off the entire sector upfront, then figure out the specifics afterward.

Investors now turn to Tuesday’s CPI data and the start of major U.S. bank earnings, with JPMorgan Chase leading off on Jan. 13. These updates could shift views on interest rates and consumer credit trends in the coming weeks. 2

Stock Market Today

AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

7 February 2026
AT&T shares closed down 0.7% at $27.13 on Friday, underperforming the S&P 500’s 1.97% gain. The company completed a $6.5 billion global notes sale this week, with maturities from 2031 to 2056 and coupons between 4.4% and 6%. Investors await delayed U.S. jobs and inflation data, along with T-Mobile’s upcoming earnings update.
GE Vernova stock price jumps toward $800 — what to know before Monday trade

GE Vernova stock price jumps toward $800 — what to know before Monday trade

7 February 2026
GE Vernova shares jumped 5.7% to $779.35 Friday after Baird upgraded the stock and the Dow closed above 50,000. The company’s onshore wind unit reported 1.1 GW in U.S. repower orders for 2025, a figure previously disclosed. GE Vernova also completed a $2.6 billion senior notes offering to help fund its Prolec GE stake purchase. Next earnings report is set for April 22.
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus
Previous Story

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface
Next Story

CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface

Go toTop